FMR, State Street and Barclays are significant holdings.
Blackrock and Vanguard not so much. They manage Mutual funds and ETFs that are based on indexes. In order to mimic the index they need to own the stocks in those indexes.
Not that long ago Jason Kolbert issued a Sell recommendation on CUR when it was trading at 80 cents. His price target was 25 cents. CUR now trades at $3.20. At the same time he issued a buy of STEM @$1.70 which is now $1. Looks to me like he was helping drum up some banking business from STEM.
RARS/MDS data is the next bomb he could drop. Life expectancy is 5-6 months and the last we heard 5 of 9 patients were still in the study. They were in the study while the hold was going on which means they were receiving clinical benefit. Given that they are in the study to date means the have well surpassed the life expectancy.
I don't have a position in this stock. I liquidated it sometime ago for the reasons I stated. I follow many of the companies in this sector, some of which I do not have a position.
I think one of the most exciting companies in this sector is OCAT. Most of their IP has been created from within the company led by one of the top pioneers/researchers in the stem cell arena (Robert Lanza). Many of these companies have acquired the IP rights from others and generate little internal IP. Their recent publication in the Lancent where 10 of 18 AMD/SMD patients had improved vision and 17 of 18 had stable vision is undeniable efficacy. One patient went from legally blind to being able to get a drivers license. This is a disease for which there is currently no treatment. This is just the tip of the iceberg of the potential of this company. The company has had a trouble financial past but I believe the next 12 months will be very good for OCAT shareholders.
I love it when you talk dirty to me like that ...
But seriously, good find. Thanks
I don't think there are any serious investors looking at this message board. It's basically some clown spamming about short hedge fund. Stemoron posting under multiple aliases misinformation about trials and lawsuits on both the CUR and STEM message boards. And many posters from the CUR message board returning the favor of the negative SPAM on the CUR message board.
You may have had success with picking stocks in the past on a technical basis but I invest on fundamentals and after years of following these stocks with moderate positions I have invested heavily in some companies in this sector recently and STEM is one of the last places I would park my money. The progress they've made, the results in the trials they've had so far are lacking. There is a reason this stock trades near its all time low with a reverse split adjusted high of $180. You can also compare the market cap to others in the sector to get an idea of what people think of STEM.
And I am a 49 year old engineer.
Soon there will be a discussion about the strange volume at the end of the day. It happens the 3rd Friday of every month. We will be hearing the "somebody knows something"
Looks like J&J just wrote a $35 mil check for Scrap value... and another possible $900 million.
Dr. T is still the lead investigator
Look at CUR. They have patients blogging about the great results. Phase 2 data should be out in a month.
MO. But good luck trying below $3. See you at $7.87
Lots of catalysts coming NSI-189 trial, China Stroke trial data, ALS trial data and an update on Spinal cord trial